← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
Dempsey Robert John
Chief Executive Officer | Officer
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0002125298
Purchase history
- Companies traded
- 1
- Purchases · 12M
- 1
- Purchases · 24M
- 1
- Average purchase
- $23.1K
- Median purchase
- $23.1K
- Gross purchase value
- $23.1K
Companies: OKYO Pharma Ltd
1 SEC accession(s) · 0 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-08-07 | OKYO Pharma Ltd | OKYO | Chief Executive Officer | Officer | $23.1K | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 1Small Sample | 100.0% (1/1) | 100.0% (1/1) | +1.6% | +1.6% | +1.6% |
| 20D | 1Small Sample | 100.0% (1/1) | 100.0% (1/1) | +5.8% | +5.8% | +5.8% |
| 60D | 0No Data | Awaiting maturity | — | — | — | — |
| 120D | 0No Data | Awaiting maturity | — | — | — | — |
Research patterns
- First purchase in 12M
- 1/1
- Large purchase ≥ $100k
- 0/1
- Cluster buying · 15D
- 1/1
- Buying the dip
- 1/1
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.